 Lipoproteins, VLDL
"Lipoproteins, VLDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of lipoproteins of very light (0.93-1.006 g/ml) large size (30-80 nm) particles with a core composed mainly of TRIGLYCERIDES and a surface monolayer of PHOSPHOLIPIDS and CHOLESTEROL into which are imbedded the apolipoproteins B, E, and C. VLDL facilitates the transport of endogenously made triglycerides to extrahepatic tissues. As triglycerides and Apo C are removed, VLDL is converted to INTERMEDIATE-DENSITY LIPOPROTEINS, then to LOW-DENSITY LIPOPROTEINS from which cholesterol is delivered to the extrahepatic tissues.
| Descriptor ID |
D008079
|
| MeSH Number(s) |
D10.532.599 D12.776.521.622
|
| Concept/Terms |
Lipoproteins, VLDL- Lipoproteins, VLDL
- VLDL Lipoproteins
- Prebeta-Lipoproteins
- Prebeta Lipoproteins
- Very-Low-Density Lipoproteins
- Lipoproteins, Very-Low-Density
- Very Low Density Lipoproteins
- Pre-beta-Lipoproteins
- Pre beta Lipoproteins
|
Below are MeSH descriptors whose meaning is more general than "Lipoproteins, VLDL".
Below are MeSH descriptors whose meaning is more specific than "Lipoproteins, VLDL".
This graph shows the total number of publications written about "Lipoproteins, VLDL" by people in this website by year, and whether "Lipoproteins, VLDL" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 0 | 2 | 2 | | 2002 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2012 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 | | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Lipoproteins, VLDL" by people in Profiles.
-
Fordham TM, Morelli NS, Garcia-Reyes Y, Ware MA, Rahat H, Sundararajan D, Fuller KNZ, Severn C, Pyle L, Malloy CR, Jin ES, Parks EJ, Wolfe RR, Cree MG. Metabolic effects of an essential amino acid supplement in adolescents with PCOS and obesity. Obesity (Silver Spring). 2024 04; 32(4):678-690.
-
Fox CK, Kaizer AM, Rudser KD, Nathan BM, Gross AC, Sunni M, Jennifer Abuzzahab M, Schwartz BL, Kumar S, Petryk A, Billington CJ, Ryder JR, Kelly AS. Meal replacements followed by topiramate for the treatment of adolescent severe obesity: A pilot randomized controlled trial. Obesity (Silver Spring). 2016 12; 24(12):2553-2561.
-
Mackey RH, Mora S, Bertoni AG, Wassel CL, Carnethon MR, Sibley CT, Goff DC. Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis. Diabetes Care. 2015 Apr; 38(4):628-36.
-
Klawitter J, Bek S, Zakaria M, Zeng C, Hornberger A, Gilbert R, Shokati T, Klawitter J, Christians U, Boernsen KO. Fatty acid desaturation index in human plasma: comparison of different analytical methodologies for the evaluation of diet effects. Anal Bioanal Chem. 2014 Oct; 406(25):6399-408.
-
Magida JA, Leinwand LA. Metabolic crosstalk between the heart and liver impacts familial hypertrophic cardiomyopathy. EMBO Mol Med. 2014 04; 6(4):482-95.
-
Bergouignan A, Momken I, Lefai E, Antoun E, Schoeller DA, Platat C, Chery I, Zahariev A, Vidal H, Gabert L, Normand S, Freyssenet D, Laville M, Simon C, Blanc S. Activity energy expenditure is a major determinant of dietary fat oxidation and trafficking, but the deleterious effect of detraining is more marked than the beneficial effect of training at current recommendations. Am J Clin Nutr. 2013 Sep; 98(3):648-58.
-
Frazier-Wood AC, Manichaikul A, Aslibekyan S, Borecki IB, Goff DC, Hopkins PN, Lai CQ, Ordovas JM, Post WS, Rich SS, Sale MM, Siscovick D, Straka RJ, Tiwari HK, Tsai MY, Rotter JI, Arnett DK. Genetic variants associated with VLDL, LDL and HDL particle size differ with race/ethnicity. Hum Genet. 2013 Apr; 132(4):405-13.
-
Strong A, Ding Q, Edmondson AC, Millar JS, Sachs KV, Li X, Kumaravel A, Wang MY, Ai D, Guo L, Alexander ET, Nguyen D, Lund-Katz S, Phillips MC, Morales CR, Tall AR, Kathiresan S, Fisher EA, Musunuru K, Rader DJ. Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest. 2012 Aug; 122(8):2807-16.
-
Rong S, Cao Q, Liu M, Seo J, Jia L, Boudyguina E, Gebre AK, Colvin PL, Smith TL, Murphy RC, Mishra N, Parks JS. Macrophage 12/15 lipoxygenase expression increases plasma and hepatic lipid levels and exacerbates atherosclerosis. J Lipid Res. 2012 Apr; 53(4):686-95.
-
Drager LF, Li J, Shin MK, Reinke C, Aggarwal NR, Jun JC, Bevans-Fonti S, Sztalryd C, O'Byrne SM, Kroupa O, Olivecrona G, Blaner WS, Polotsky VY. Intermittent hypoxia inhibits clearance of triglyceride-rich lipoproteins and inactivates adipose lipoprotein lipase in a mouse model of sleep apnoea. Eur Heart J. 2012 Mar; 33(6):783-90.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|